The estimated Net Worth of Antony Koblish is at least 3.2 百万$ dollars as of 14 November 2023. Mr. Koblish owns over 11,000 units of TELA Bio stock worth over 801,594$ and over the last 5 years he sold TELA stock worth over 0$. In addition, he makes 2,399,600$ as President、 Chief Executive Officer、 Co-Founder、 Director at TELA Bio.
Antony has made over 1 trades of the TELA Bio stock since 2023, according to the Form 4 filled with the SEC. Most recently he bought 11,000 units of TELA stock worth 49,940$ on 14 November 2023.
The largest trade he's ever made was buying 11,000 units of TELA Bio stock on 14 November 2023 worth over 49,940$. On average, Antony trades about 1,000 units every 0 days since 2019. As of 14 November 2023 he still owns at least 303,634 units of TELA Bio stock.
You can see the complete history of Mr. Koblish stock trades at the bottom of the page.
Antony Koblish serves as President, Chief Executive Officer, Co-Founder, Director of the Company. Antony Koblish is one of our co-founders and has served as our President and Chief Executive Officer and as a member of the Board since our founding in April 2012. Previously, Mr. Koblish was President and Chief Executive Officer of Orthovita, Inc., a publicly traded orthobiologics and biosurgery medical device company. Mr. Koblish co-founded and currently serves as Chairman of the Board of Onkos Surgical, a surgical oncology company, and is an operating partner with 1315 Capital, a private investment firm that provides expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology, and health care services companies. Mr. Koblish also serves as the Chairman of the Board of Cerapedics, a private ortho-biologics company. As Chairman of the Board of Cerapedics and Onkos Surgical Mr. Koblish attends one board meeting per quarter, respectively, and as an operating partner for 1315 Capital Mr. Koblish attends one to two meetings per quarter. The remainder of Mr. Koblish’s time is dedicated to serving as our Chief Executive Officer. Mr. Koblish earned a Master of Science in Engineering degree in Mechanical Engineering and Applied Mechanics from the University of Pennsylvania, and holds a Bachelor of Science degree in Mechanical Engineering from Worcester Polytechnic Institute.
As the President、 Chief Executive Officer、 Co-Founder、 Director of TELA Bio, the total compensation of Antony Koblish at TELA Bio is 2,399,600$. There are no executives at TELA Bio getting paid more.
Antony's mailing address filed with the SEC is C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN, PA, 19355.
Over the last 5 years, insiders at TELA Bio have traded over 4,222,376$ worth of TELA Bio stock and bought 4,343,227 units worth 46,898,981$ . The most active insiders traders include Management Inc. Opaleye、Investments, Lpwong Roderic...、Advisors Llc Orbi Med Capit.... On average, TELA Bio executives and independent directors trade stock every 18 days with the average trade being worth of 139,070$. The most recent stock trade was executed by Advisors Llc Orbi Med Capit... on 28 June 2024, trading 428,300 units of TELA stock currently worth 2,021,576$.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
TELA Bio executives and other stock owners filed with the SEC include: